Live feed07:00:00·260dPRReleasevia QuantisnowBioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other CancersByQuantisnow·Wall Street's wire, on your screen.BLRX· BioLineRx Ltd.Health Care
